Promoter holding
64.27%
KP
Kwality Pharmaceuticals Limited - Due diligence report
A 360° intelligence report on Kwalitypharma: trust score, financial health, credit view, compliance, directors, growth and distress signals …
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Kwalitypharma — 360° Intelligence Report
Generated from MCA filings & public records71/100
Trust Score
Moderate
Kwalitypharma is assessed as Moderate with a Trust Score of 71/100. Kwalitypharma is an active public limited indian non-government company incorporated in 1983, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and low financial risk profile.
Report generated on 18 Jul 2026 from the latest processed filings. Kwality Pharmaceuticals Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
71/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
36/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
90/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 90/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Open charges exceed net worth - secured lenders rank ahead.
- Moderate gearing (D/E 1.42).
- Working-capital cover adequate.
- Profitable - internal accruals available.
- Externally credit-rated (BBB).
Charges position: 20 open (206.19 cr) · 19 satisfied (25.45 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Hdfc Bank Limited | 17 | 48.0 cr |
| Axis Bank Limited | 1 | 48.0 cr |
| Others | 6 | 48.0 cr |
| Bank Of India | 11 | 48.0 cr |
| State Bank Of India | 1 | 48.0 cr |
| Bank Of Punjab Ltd | 1 | 48.0 cr |
Compliance Score: 36/100 Caution Indicated
- Company status is Active as per MCA.
- Balance sheet slightly behind (Mar 2024).
- Flagged by authority: EPFO, BSE.
- Litigation present in 2 court forum(s).
- Delayed payments to MSME suppliers disclosed (380 disclosure(s)).
- 3 active GST registration(s).
Legal cases on record (2)
05
Director Intelligence
Stability score: 90/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| RAMESH ARORA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| AJAY KUMAR ARORA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| GEETA ARORA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ANJU ARORA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KARTIK KAPUR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| GURPREET KAUR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ADITYA ARORA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PRASHANTH VELLANKI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAVI SHANKER SINGH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KIRAN KUMAR VERMA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VINOD KUMAR SHARMA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ADITYA ARORA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PANKAJ TAKKAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 13 directors on the board.
- No disqualified or deactivated DINs.
- 1 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
5 allotment(s) · 0 transfer(s)
Promoters hold a majority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Kwality Pharmaceuticals Africa Limitada | Subsidiary Company | 74.00% |
Key managerial personnel: RAMESH ARORA (Managing Director) · AJAY KUMAR ARORA (Whole-time director) · GEETA ARORA (Whole-time director) · ADITYA ARORA (CFO) · ADITYA ARORA (Whole-time director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 75 · Distress 75
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
EPFO headcount growing - hiring signal.
Operating for 43+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Compliance score is weak (36/100).
20 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 14.10 cr.
2 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence58/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment74/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 20 open charge(s) of 206.19 cr already registered.
- Compliance gaps should be priced into terms.
Investor view76/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 2 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events15 Oct 2025
Charge created
Hdfc Bank Limited - 10.09 Lakh
14 Oct 2025
Charge created
Hdfc Bank Limited - 2.51 cr
29 Sep 2025
Charge created
Others - 27.30 Lakh
08 Sep 2025
Director ceased
VINOD KUMAR SHARMA
07 Aug 2025
Charge created
Hdfc Bank Limited - 15.10 Lakh
04 Aug 2025
Charge created
Others - 25.00 Lakh
26 Jul 2025
Director appointed
VINOD KUMAR SHARMA (Director)
05 Jul 2025
Director appointed
ANJU ARORA (Deputy Nodal Officer)
07 May 2025
Charge created
Others - 25.00 Lakh
28 Apr 2025
Charge created
Others - 5.00 cr
18 Mar 2025
Charge satisfied
Hdfc Bank Limited
04 Mar 2025
Charge satisfied
Hdfc Bank Limited
16 Dec 2024
Charge created
Others - 1.30 cr
24 Sep 2024
Last AGM held
Annual general meeting
23 Aug 2024
Charge created
Hdfc Bank Limited - 26.93 Lakh
10
Key Observations
Auto-generated from the data aboveRevenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Debt-to-equity stands at 38% - manageable leverage.
Net worth is positive.
13 active director(s) / partner(s); board looks stable and experienced.
3 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of BBB from Icra.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 5 security allotment(s) - amounts available in the full report.
1 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Styrax Pharma | U24230AP1995PTC098146 | Vishakapatnam, Andhra Pradesh, India |
| Oaknet | U74999GJ2011PTC145203 | Ahmadabad City, Gujarat, India |
| Nitin Lifesciences | U73100HP2005PLC028049 | Paonta Sahib, Himachal Pradesh, India |
| Resins And Plastics | U25209MH1961PLC012223 | Mumbai, Maharashtra, India |
| Rakshit Pharmaceuticals Limited | U24239TG2005PLC048151 | Shaikpet, Telangana, India |
| R3Cropcare | U24210MH1992PTC066957 | Mumbai, Maharashtra, India |
| Vetoquinol | U85200MH2009PTC192526 | Thane West, Maharashtra, India |
| Troy | U24233MH2012FTC238174 | Mumbai, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Kwalitypharma before audits and certifications: compliance score 36/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Kwalitypharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 90/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 75/100, margin trends, ownership structure and peer set for Kwalitypharma - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 71/100, distress signals and MSME payment-delay disclosures - know whether Kwalitypharma pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Kwalitypharma - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Kwalitypharma an active company?
Kwalitypharma has MCA status “Active” with a compliance score of 36/100 (Caution Indicated).
Is Kwalitypharma financially healthy?
Kwalitypharma has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.
Should I do business with Kwalitypharma?
Its overall Trust Score is 71/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Kwalitypharma?
Promoters hold a majority stake - exact percentages are in the full report. 13 active director(s) are on record.
Does Kwalitypharma have loans or charges against its assets?
20 open charge(s) are registered against its assets, and 19 earlier charge(s) stand satisfied.
Is Kwalitypharma up to date with its ROC filings?
Balance sheet slightly behind (Mar 2024). Overall compliance score: 36/100 (Caution Indicated).
Is it risky to lend to Kwalitypharma?
Its Credit Risk Score is 90/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
